APTO-253

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameAPTO-253
Drug Alias NameLT-253LOR-253LOR-253-HClAPTO-253
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionApoptosis stimulantsMyc proto-oncogene protein inhibitorsKruppel-like factor 4 stimulants +[4] 
TargetsMyc proto-oncogene proteinMetal regulatory transcription factor 1Kruppel-like factor 4
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAptose
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAptose Biosciences Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A